
What is claimed is:

1. A compound of Formula (I):



(I)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; wherein:

R^1 is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^2 is $–C(O)OR^{2a}$, $–C(O)NR^{2b}R^{2c}$, $–C(O)N(R^{2b})OR^{2c}$, or heteroaryl; wherein R^{2a}, R^{2b}, and R^{2c} are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

R^3, R^4, R^5, and R^6 are each independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $–C(O)R^{1a}$, $–C(O)OR^{1a}$, $–C(O)NR^{1b}R^{1c}$, $–C(NR^{1a})NR^{1b}R^{1c}$, $–OR^{1a}$, $–OC(O)R^{1a}$, $–OC(O)OR^{1a}$, $–OC(O)NR^{1b}R^{1c}$, $–OC(NR^{1a})NR^{1b}R^{1c}$, $–OS(O)R^{1a}$, $–OS(O)_2R^{1a}$, $–OS(O)NR^{1b}R^{1c}$, $–OS(O)_2NR^{1b}R^{1c}$, $–NR^{1b}R^{1c}$, $–NR^{1a}C(O)R^{1d}$, $–NR^{1a}C(O)OR^{1d}$, $–NR^{1a}C(O)NR^{1b}R^{1c}$, $–NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $–NR^{1a}S(O)R^{1d}$, $–NR^{1a}S(O)_2R^{1d}$, $–NR^{1a}S(O)NR^{1b}R^{1c}$, $–NR^{1a}S(O)_2NR^{1b}R^{1c}$, $–SR^{1a}$, $–S(O)R^{1a}$, $–S(O)_2R^{1a}$, $–S(O)NR^{1b}R^{1c}$, or $–S(O)_2NR^{1b}R^{1c}$;

R^A is C_{6-14} arylene or heteroarylene;

R^B and X are (i) or (ii):

(i) X is –O–, –S–, –S(O)–, or $–S(O)_2–$; and

R^B is C_{6-14} aryl or heteroaryl;

(ii) X is $–N(R^X)–$;

R^B is C_{6-14} aryl or heteroaryl; and

R^X is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

L is C_{1-6} alkylene, C_{2-6} alkenylene, C_{3-10} cycloalkylene, or heterocyclylene; and

each R^{1a}, R^{1b}, R^{1c}, and R^{1d} is independently hydrogen, deuterium, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or R^{1a} and R^{1c} together with the C and N atoms to which they are attached form heterocyclyl; or R^{1b} and R^{1c} together with the N atom to which they are attached form heterocyclyl;

wherein each alkyl, alkylene, alkenyl, alkenylene, alkynyl, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, and heterocyclyl; and (c) $–C(O)R^a$, $–C(O)OR^a$, $–C(O)NR^bR^c$, $–C(O)SR^a$, $–C(NR^a)NR^bR^c$, $–C(S)R^a$, $–C(S)OR^a$, $–C(S)NR^bR^c$, $–OR^a$, $–OC(O)R^a$, $–OC(O)OR^a$, $–OC(O)NR^bR^c$, $–OC(O)SR^a$, $–OC(NR^a)NR^bR^c$, $–OC(S)R^a$, $–OC(S)OR^a$, $–OC(S)NR^bR^c$, $–OS(O)R^a$, $–OS(O)_2R^a$, $–OS(O)NR^bR^c$, $–OS(O)_2NR^bR^c$, $–NR^bR^c$, $–NR^aC(O)R^d$, $–NR^aC(O)OR^d$, $–NR^aC(O)NR^bR^c$, $–NR^aC(O)SR^d$, $–NR^aC(NR^d)NR^bR^c$, $–NR^aC(S)R^d$, $–NR^aC(S)OR^d$, $–NR^aC(S)NR^bR^c$, $–NR^aS(O)R^d$, $–NR^aS(O)_2R^d$, $–NR^aS(O)NR^bR^c$, $–NR^aS(O)_2NR^bR^c$, $–SR^a$, $–S(O)R^a$, $–S(O)_2R^a$, $–S(O)NR^bR^c$, and $–S(O)_2NR^bR^c$, wherein each R^a, R^b, R^c, and R^d is independently (i) hydrogen or deuterium; (ii) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (iii) R^b and R^c together with the N atom to which they are attached form heterocyclyl.

2. The compound of claim 1,

wherein R^A is C_{6-14} arylene, optionally substituted with one or more substituents Q; or

wherein R^A is heteroarylene, optionally substituted with one or more substituents Q; or


wherein R^A is monocyclic heteroarylene, optionally substituted with one or more substituents Q; or

wherein R^A is 6-membered heteroarylene, optionally substituted with one or more substituents Q; or

wherein R^A is pyridylene, optionally substituted with one or more substituents Q.

3. The compound of claim 1 or 2,

having the structure of Formula (III):



(III)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; wherein:

U^1, V^1, W^1, and X^1 are each independently (i) C or N; or (ii) $–CR^{7a}=$, –N=, $–NR^{7b}–$, –O–, or –S–;

Y^1 is (i) C or N; or (ii) a bond, $–CR^{7a}=$, –N=, $–NR^{7b}–$, –O–, or –S–;


Z^1 is C or N;

each R^{7a} is independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl; or (c) $–C(O)R^{1a}$, $–C(O)OR^{1a}$, $–C(O)NR^{1b}R^{1c}$, $–C(NR^{1a})NR^{1b}R^{1c}$, $–OR^{1a}$, $–OC(O)R^{1a}$, $–OC(O)OR^{1a}$, $–OC(O)NR^{1b}R^{1c}$, $–OC(NR^{1a})NR^{1b}R^{1c}$, $–OS(O)R^{1a}$, $–OS(O)_2R^{1a}$, $–OS(O)NR^{1b}R^{1c}$, $–OS(O)_2NR^{1b}R^{1c}$, $–NR^{1b}R^{1c}$, $–NR^{1a}C(O)R^{1d}$, $–NR^{1a}C(O)OR^{1d}$, $–NR^{1a}C(O)NR^{1b}R^{1c}$, $–NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $–NR^{1a}S(O)R^{1d}$, $–NR^{1a}S(O)_2R^{1d}$, $–NR^{1a}S(O)NR^{1b}R^{1c}$, $–NR^{1a}S(O)_2NR^{1b}R^{1c}$, $–SR^{1a}$, $–S(O)R^{1a}$, $–S(O)_2R^{1a}$, $–S(O)NR^{1b}R^{1c}$, or $–S(O)_2NR^{1b}R^{1c}$; and

each R^{7b} is independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl;

wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more substituents Q; or

having the structure of Formula (IX):



(IX)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; wherein:

each R^7 is independently (a) deuterium, cyano, halo, or nitro; (b) C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{6-14} aryl, C_{7-15} aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more substituents Q; or (c) $–C(O)R^{1a}$, $–C(O)OR^{1a}$, $–C(O)NR^{1b}R^{1c}$, $–C(NR^{1a})NR^{1b}R^{1c}$, $–OR^{1a}$, $–OC(O)R^{1a}$, $–OC(O)OR^{1a}$, $–OC(O)NR^{1b}R^{1c}$, $–OC(NR^{1a})NR^{1b}R^{1c}$, $–OS(O)R^{1a}$, $–OS(O)_2R^{1a}$, $–OS(O)NR^{1b}R^{1c}$, $–OS(O)_2NR^{1b}R^{1c}$, $–NR^{1b}R^{1c}$, $–NR^{1a}C(O)R^{1d}$, $–NR^{1a}C(O)OR^{1d}$, $–NR^{1a}C(O)NR^{1b}R^{1c}$, $–NR^{1a}C(NR^{1d})NR^{1b}R^{1c}$, $–NR^{1a}S(O)R^{1d}$, $–NR^{1a}S(O)_2R^{1d}$, $–NR^{1a}S(O)NR^{1b}R^{1c}$, $–NR^{1a}S(O)_2NR^{1b}R^{1c}$, $–SR^{1a}$, $–S(O)R^{1a}$, $–S(O)_2R^{1a}$, $–S(O)NR^{1b}R^{1c}$, or $–S(O)_2NR^{1b}R^{1c}$; and

n is an integer of 0, 1, 2, 3, or 4.

4. The compound of any one of claims 1 to 3,

wherein L is C_{1-6} alkylene, optionally substituted with one or more substituents Q; or wherein L is methylene, ethylene, or propylene, each of which is optionally substituted with one or more substituents Q; or wherein L is C_{2-6} alkenylene, optionally substituted with one or more substituents Q; or, wherein L is ethenylene, optionally substituted with one or more substituents Q; and/or


wherein X is –O– or $–NR^X–$, wherein R^X is (i) hydrogen; or (ii) C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl, each of which is optionally substituted with one or more substituents Q; or wherein X is –O–; and/or

wherein R^2 is $–C(O)OR^{2a}$; or wherein R^2 is –C(O)OH; or wherein R^2 is $–C(O)NR^{2b}R^{2c}$; or wherein R^2 is $–C(O)NHR^{2c}$, and R^{2c} is C_{1-6} alkyl or heteroaryl, each of which is optionally substituted with one or more substituents Q; or wherein R^2 is $–C(O)NH_2$, $–C(O)NHCH_3$,

–C(O)NHCH$_2$CH$_2$OH, or –C(O)NH(tetrazolyl); or wherein R^2 is –C(O)N(R^{2b})OR^{2c}; or R^2 is –C(O)NHOR^{2c}; or wherein R^2 is –C(O)NHOH.

5. The compound of any one of claims 1 to 4,


having the structure of Formula (XIV):



(XIV)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or


having the structure of Formula (XV):



(XV)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or


having the structure of Formula (XVI):



(XVI)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or


having the structure of Formula (XVIII):



(XVIII)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or

having the structure of Formula (XVII):



(XVII)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof;

wherein R^{2A} is $–OR^{2a}$, $–NR^{2b}R^{2c}$, or $–N(R^{2b})OR^{2c}$; and p is an integer of 1, 2, or 3;

optionally wherein R^7 is deuterium, halo, or $–O–C_{1\text{-}6}$ alkyl optionally substituted with one or more substituents Q; or wherein R^7 is chloro or methoxy; or

optionally wherein R^{7a} is hydrogen, deuterium, halo, or $–O–C_{1\text{-}6}$ alkyl optionally substituted with one or more substituents Q; or wherein R^{7a} is hydrogen, deuterium, chloro, or methoxy.

6. The compound of any one of claims 1 to 5,

wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q; or

wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q, each of which is independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, methoxy, and formyl; or


wherein R^B is phenyl, naphthyl, pyridyl, or quinolinyl, each of which is optionally substituted with one or more substituents Q, each of which is independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, and methoxy; or

wherein R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; or

wherein R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl.

7. The compound of any one of claims 1 to 4,


having the structure of Formula (XIX):



(XIX)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or


having the structure of Formula (XX):



(XX)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or


having the structure of Formula (XXI):



(XXI)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or


having the structure of Formula (XXIII):



(XXIII)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or

having the structure of Formula (XXII):



(XXII)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof;

optionally wherein R^7 is deuterium, halo, or –O–C_{1-6} alkyl optionally substituted with one or more substituents Q; or wherein R^7 is chloro or methoxy; or

optionally wherein R^{7a} is hydrogen, deuterium, halo. or –O–C_{1-6} alkyl optionally substituted with one or more substituents Q; or wherein R^{7a} is hydrogen, deuterium, chloro, or methoxy.

8. The compound of claim 7,

wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q; or wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q, each of which is independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, methoxy, and formyl; or wherein R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; or wherein R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl,

2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and/or

wherein R^X is (i) hydrogen; or (ii) C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl, each of which is optionally substituted with one, two, or three substituents Q; or wherein R^X is (i) hydrogen; or (ii) C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl, each of which is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, methoxy, and formyl; or wherein R^X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or wherein R^X is hydrogen, methyl, ethyl, 2-hydroxyethyl, *n*-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl.

9. The compound of any one of claims 5 to 8,

wherein R^{2A} is $–OR^{2a}$; or

wherein R^{2A} is –OH; or

wherein R^{2A} is $–NR^{2b}R^{2c}$; or

wherein R^{2A} is $–NHR^{2c}$, and R^{2c} is C_{1-6} alkyl or heteroaryl, each of which is optionally substituted with one or more substituents Q; or

wherein R^{2A} is $–NH_2$, $–NHCH_3$, $–NHCH_2CH_2OH$, or –NH(tetrazolyl); or

wherein R^{2A} is $–N(R^{2b})OR^{2c}$; or

wherein R^{2A} is $–NHOR^{2c}$; or

wherein R^{2A} is –NHOH.

10. The compound of any one of claims 1 to 4 and 6,


wherein R^2 is heteroaryl, optionally substituted with one or more substituents Q; or

wherein R^2 is monocyclic heteroaryl, optionally substituted with one or more substituents Q; or

wherein R^2 is 5-membered heteroaryl, optionally substituted with one or more substituents Q.

11. The compound of any one of claims 1 to 4, 6, and 10,


having the structure of Formula (XXIV):



(XXIV)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or


wherein the compound is a compound of Formula (XXV):



(XXV)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or


wherein the compound is a compound of Formula (XXVI):



(XXVI)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or


wherein the compound is a compound of Formula (XXVIII):



(XXVIII)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or

wherein the compound is a compound of Formula (XXVII):



(XXVII)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof;

wherein U^2 is –N= or –O–; and V^2 is –N= or –C(OH)=;

optionally wherein R^7 is deuterium, halo, or –O–C_{1-6} alkyl optionally substituted with one or more substituents Q; or wherein R^7 is chloro or methoxy; or

optionally wherein R^{7a} is hydrogen, deuterium, halo, or –O–C_{1-6} alkyl optionally substituted with one or more substituents Q; or wherein R^{7a} is hydrogen, deuterium, chloro, or methoxy.

12. The compound of claim 11,

wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q; or

wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl,

each of which is optionally substituted with one or more substituents Q, each of which is independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, methoxy, and formyl; or


wherein R^B is phenyl, naphthyl, pyridyl, or quinolinyl, each of which is optionally substituted with one or more substituents Q, each of which is independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, and methoxy; or

wherein R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; or

wherein R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl.

13. The compound of any one of claims 1 to 3 and 10,


having the structure of Formula (XXIX):



(XXIX)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or


having the structure of Formula (XXX):



(XXX)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or


having the structure of Formula (XXXI):



(XXXI)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or


having the structure of Formula (XXXIII):



(XXXIII)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; or

having the structure of Formula (XXXII):



(XXXII)

or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof;

optionally wherein R^7 is deuterium, halo, or –O–C_{1-6} alkyl optionally substituted with one or more substituents Q; or wherein R^7 is chloro or methoxy; or

optionally wherein R^{7a} is hydrogen, deuterium, halo. or –O–C_{1-6} alkyl optionally substituted with one or more substituents Q; or wherein R^{7a} is hydrogen, deuterium, chloro, or methoxy.

14. The compound of claim 13,

wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q; or wherein R^B is monocyclic or bicyclic C_{6-14} aryl, or monocyclic or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents Q, each of which is independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, methoxy, and formyl; or wherein R^B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; or wherein R^B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2,4-difluorophenyl, 2,4,5-trifluorophenyl, naphth-2-yl,

2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and/or

wherein R^X is (i) hydrogen; or (ii) C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl, each of which is optionally substituted with one, two, or three substituents Q; or wherein R^X is (i) hydrogen; or (ii) C_{1-6} alkyl, C_{6-14} aryl, or C_{7-15} aralkyl, each of which is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, hydroxyl, methoxy, and formyl; or wherein R^X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or wherein R^X is hydrogen, methyl, ethyl, 2-hydroxyethyl, *n*-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; and/or

wherein U^2 is –N=; or wherein U^2 is –O–; and/or

wherein V^2 is –N=; or wherein V^2 is –C(OH)=; or

wherein U^2 and V^2 are each –N=; or wherein U^2 is –O– and V^2 is –C(OH)=.

15. The compound of any one of claims 1 to 14,

wherein R^1 is hydrogen, deuterium, or methyl; and/or

wherein R^3 is hydrogen, deuterium, halo, or C_{1-6} alkyl optionally substituted with one, two, or three substituents Q; or wherein R^3 is hydrogen, deuterium, or methyl; and/or

wherein R^4 is hydrogen, deuterium, halo, or C_{1-6} alkyl optionally substituted with one, two, or three substituents Q; or wherein R^4 is hydrogen or deuterium; or wherein R^4 is halo; or wherein R^4 is fluoro; or wherein R^4 is C_{1-6} alkyl, optionally substituted with one, two, or three substituents Q; or wherein R^4 is methyl; and/or

wherein R^5 is hydrogen or deuterium; and/or

wherein R^6 is hydrogen or deuterium.

16. A compound of:

2-[(1*Z*)-5-fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]acetic acid **A1**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-methoxyphenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A2**;

2-[(1*Z*)-1-({2-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A3**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(4-methylphenoxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **A4**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **A5**;

2-[(1*Z*)-1-{[4-(4-bromophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A6**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(3-methylphenoxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **A7**;

2-[(1*Z*)-1-{[4-(3-cyanophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A8**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-(3-(trifluoromethyl)phenoxy)benzylidene)-1*H*-inden-3-yl)acetic acid **A9**;

2-[(1*Z*)-1-{[4-(4-ethylphenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A10**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A11**;

2-[(1Z)-1-{[2-chloro-4-(4-methoxyphenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A12**;

2-[(1*Z*)-5-fluoro-1-({2-methoxy-4-[4-(propan-2-yl)phenoxy]phenyl}-methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A13**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(naphthalen-2-yloxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **A14**;

2-[(1*Z*)-1-({2-chloro-4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A15**;

2-[(1*Z*)-1-{[4-(2,4-difluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A16**;

2-[(1*Z*)-1-{[4-(2-bromo-4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A17**;

2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(2,4,5-trifluorophenoxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **A18**;

3-[(1*Z*)-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-

yl]propanoic acid **A19**;

2-[(1*Z*)-5-fluoro-1-({4-[(6-fluoropyridin-3-yl)oxy]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A20**;

2-[(1*Z*)-5-fluoro-1-({4-[(6-fluoro-5-methylpyridin-3-yl)oxy]phenyl}-methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A21**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-(quinolin-5-yloxy)benzylidene)-1*H*-inden-3-yl)acetic acid **A22**;

2-[(1*Z*)-5-fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A23**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A24**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetamide **A25**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-methylacetamide **A26**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-(2-hydroxyethyl)acetamide **A27**;

(*Z*)-2-(5-fluoro-2-methyl-1-(4-phenoxybenzylidene)-1*H*-inden-3-yl)-*N*-(1*H*-tetrazol-5-yl)acetamide **A28**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[methyl(phenyl)amino]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **A29**;

2-[(1*Z*)-1-({4-[benzyl(4-fluorophenyl)amino]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A30**;

2-[(1*Z*)-5-fluoro-1-({4-[(4-fluorophenyl)(methyl)amino]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A31**;

2-[(1*Z*)-1-({4-[ethyl(4-fluorophenyl)amino]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A32**;

2-[(1*Z*)-5-fluoro-1-({4-[(4-fluorophenyl)(propyl)amino]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A33**;

(*Z*)-2-(5-fluoro-1-(4-((4-fluorophenyl)(2-hydroxyethyl)amino)benzylidene)-2-methyl-1*H*-inden-3-yl)acetic acid **A34**;

2-[(1*Z*)-5-fluoro-1-({4-[(4-fluorophenyl)(4-formylphenyl)amino]phenyl}-methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A35**;

2-[(1*Z*)-5-fluoro-1-({4-[(4-formylphenyl)(phenyl)amino]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A36**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[methyl(phenyl)amino]phenyl}methylidene)-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A37**;

2-[(1*Z*)-1-({4-[benzyl(4-fluorophenyl)amino]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]-N-hydroxyacetamide **A38**;

5-{[(1*Z*)-2-methyl-1-[(3-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl}-1*H*-1,2,3,4-tetrazole **A39**;

5-{[(1*Z*)-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl}-1*H*-1,2,3,4-tetrazole **A40**;

5-{2-[(1*Z*)-2-methyl-1-{[4-(4-methylphenoxy)phenyl]methylidene}-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A41**;

5-{2-[(1*Z*)-1-{[4-(4-bromophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A42**;

5-{2-[(1*Z*)-2-methyl-1-({4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A43**;

5-{2-[(1*Z*)-1-{[4-(4-methoxyphenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A44**;

5-{2-[(1*Z*)-2-methyl-1-({4-[4-(trifluoromethyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A45**;

5-{2-[(1*Z*)-2-methyl-1-{[4-(3-methylphenoxy)phenyl]methylidene}-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A46**;

3-(4-{[(1*Z*)-2-methyl-3-[2-(1*H*-1,2,3,4-tetrazol-5-yl)ethyl]-1*H*-inden-1-ylidene]methyl}phenoxy)benzonitrile **A47**;

5-{2-[(1*Z*)-1-{[4-(3-methoxyphenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A48**;

5-{2-[(1*Z*)-1-{[4-(3-bromophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A49**;

5-{2-[(1*Z*)-2-methyl-1-({4-[3-(trifluoromethyl)phenoxy]phenyl}methylidene)-

1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A50**;

5-{2-[(1*Z*)-2-methyl-1-{[4-(naphthalen-2-yloxy)phenyl]methylidene}-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **A51**;

(*Z*)-3-((2-methyl-1-(4-phenoxybenzylidene)-1*H*-inden-3-yl)methyl)-1,2,4-oxadiazol-5(4*H*)-one **A52**;

5-{[(1*E*)-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl}-1*H*-1,2,3,4-tetrazole **A53**;

5-{[(1*E*)-1-[(3-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]methyl}-1*H*-1,2,3,4-tetrazole **A54**;

(2*E*)-3-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]prop-2-enoic acid **A61**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorobenzenesulfonyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A62**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorobenzenesulfinyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A63**;

2-[(1*Z*)-5-fluoro-1-({4-[(4-fluorophenyl)sulfanyl]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]acetic acid **A64**;

2-[(1*Z*)-5-fluoro-1-{[6-(4-fluorophenoxy)pyridine-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A65**;

2-[(1*Z*)-5-fluoro-1-{[6-(4-fluorophenoxy)-5-methylpyridin-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A66**;

(2*E*)-4-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]but-2-enoic acid **A67**;

2-[(1*Z*)-4,5-difluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]acetic acid **A68**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2,4-dimethyl-1*H*-inden-3-yl]acetic acid **A69**;

(2*E*)-3-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyprop-2-enamide **A76**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorobenzenesulfonyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A77**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorobenzenesulfinyl)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A78**;

2-[(1*Z*)-5-fluoro-1-({4-[(4-fluorophenyl)sulfanyl]phenyl}methylidene)-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A79**;

2-[(1*Z*)-5-fluoro-1-{[6-(4-fluorophenoxy)pyridine-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A80**;

2-[(1*Z*)-5-fluoro-1-{[6-(4-fluorophenoxy)-5-methylpyridin-3-yl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A81**;

(2*E*)-4-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxybut-2-enamide **A82**;

2-[(1*Z*)-4,5-difluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A83**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2,4-dimethyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A84**; or

2-[(1*Z*)-5-Fluoro-1-({4-[(4-fluorophenyl)(2-hydroxyethyl)amino]phenyl}-methylidene)-2-methyl-1*H*-inden-3-yl]-*N*-hydroxyacetamide **A85**;

2-[(1*Z*)-5-fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]-*N*-hydroxy-*N*-methylacetamide **C1**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1*H*-inden-3-yl]−*N*-hydroxy-*N*-methylacetamide **C2**;

(*Z*)-2-(5-fluoro-2-methyl-1-(3-phenoxybenzylidene)-1*H*-inden-3-yl)-N-hydroxy-*N*-methylacetamide **C3**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]-*N*-hydroxyacetamide **D1**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[4-(*tert*-butyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D2**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[3-(*tert*-butyl)phenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D3**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[3-fluoro-4-methylphenoxy]phenyl}-methylidene)-1*H*-inden-3-yl]acetic acid **D4**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[3,4-difluorophenoxy]phenyl}methylidene)-1*H*-

inden-3-yl]acetic acid **D5**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[3-nitrophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D6**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({4-[4-(trifluoromethyl)phenoxy]phenyl}-methylidene)-1*H*-inden-3-yl]acetic acid **D7**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-(2-methyl-propyl)-1*H*-inden-3-yl]acetic acid **D8**;

2-[(1*Z*)-5-fluoro-2-benzyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D9**;

2-[(1*Z*)-5-methoxy-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D10**;

2-[(1*Z*)-5-methoxy-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]acetic acid **D11**;

2-[(1*Z*)-1-{[2-trifluoromethyl-4-(4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **D12**;

2-[(1*Z*)-1-{[3-methyl-4-(4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **D13**;

2-[(1*Z*)-1-{[2-methyl-4-(4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **D14**;

2-[(1*Z*)-5,7-difluoro-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D15**;

2-[(1*Z*)-4,6-difluoro-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D16**;

2-[(1*Z*)-5-*tert*-butyl-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D17**;

(*Z*)-2-(5-fluoro-2-methyl-1-(3-phenoxybenzylidene)-1*H*-inden-3-yl)acetic acid **D18**;

2-[(1*Z*)-5-fluoro-1-(2-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D19**;

2-[(1*Z*)-5,7-difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D20**;

2-[(1*Z*)-4,6-difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D21**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({3-[4-methoxyphenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D22**;

2-[(1*Z*)-5-fluoro-1-(4-fluoro-3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D23**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({3-[4-cyanophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D24**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({3-[4-chlorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D25**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({3-[4-trifluoromethylphenoxy]phenyl}-methylidene)-1*H*-inden-3-yl]acetic acid **D26**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({3-[3-trifluoromethylphenoxy]phenyl}-methylidene)-1*H*-inden-3-yl]acetic acid **D27**;

2-[(1*Z*)-4-methoxy-1-(4-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D28**;

2-[(1*Z*)-6-methoxy-1-(4-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D29**;

2-[(1*Z*)-6-trifluoromethyl-2-methyl-1-({4-[4-fluorophenoxy]phenyl}-methylidene)-1*H*-inden-3-yl]acetic acid **D30**;

2-[(1*Z*)-5-trifluoromethyl-2-methyl-1-({4-[4-fluorophenoxy]phenyl}-methylidene)-1*H*-inden-3-yl]acetic acid **D31**;

2-[(1*Z*)-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **D32**;

2-[(1*Z*)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **D33**;

2-[(1*Z*)-5-trifluoromethyl-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D34**;

2-[(1*Z*)-6-methoxy-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D35**;

2-[(1*Z*)-6-trifluoromethyl-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-

acetic acid **D36**;

2-[(1*Z*)-5-fluoro-2-methyl-1-({3-[methyl(phenyl)amino]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D37**;

2-[(1*Z*)-5-fluoro-1-[(3-methoxy-5-phenoxyphenyl)methylidene]-2-methyl-1*H*-inden-3-yl]acetic acid **D38**;

2-[(1*E*)-5-fluoro-2-methyl-1-({4-[3,4-difluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **E1**;

2-[(1*E*)-5-fluoro-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **E2**;

2-[(1*E*)-5-fluoro-2-methyl-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]acetic acid **E3**;

2-[(1*E*)-5,7-difluoro-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **E4**;

5-{2-[(1*E*)-1-[(4-phenoxyphenyl)methylidene]-1*H*-inden-3-yl]ethyl}-1*H*-1,2,3,4-tetrazole **E5**; and

2-[(1*E*)-5,7-difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **E6**;

or a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

17. The compound of claim 16, wherein the compound is 2-[(1Z)-5-fluoro-1-{[4-(4-fluorophenoxy)phenyl]methylidene}-2-methyl-1H-inden-3-yl]acetic acid **A11** or a pharmaceutically acceptable salt thereof.

18. The compound of claim 16, wherein the compound is 2-[(1*Z*)-1-{[2-chloro-4-(4-methoxyphenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A12** or a pharmaceutically acceptable salt thereof.

19. The compound of claim 16, wherein the compound is 2-[(1*Z*)-5-fluoro-2-methyl-1-{[4-(naphthalen-2-yloxy)phenyl]methylidene}-1*H*-inden-3-yl]acetic acid **A14** or a pharmaceutically acceptable salt thereof.

20. The compound of claim 16, wherein the compound is 2-[(1*Z*)-1-({2-chloro-4-[4-(propan-2-yl)phenoxy]phenyl}methylidene)-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **A15** or a pharmaceutically acceptable salt thereof.

21. The compound of claim 16, wherein the compound is 2-[(1*Z*)-1-{[2-methyl-4-(4-fluorophenoxy)phenyl]methylidene}-5-fluoro-2-methyl-1*H*-inden-3-yl]acetic acid **D14** or a pharmaceutically acceptable salt thereof.

22. The compound of claim 16, wherein the compound is 2-[(1*Z*)-5,7-difluoro-2-methyl-1-({4-[4-fluorophenoxy]phenyl}methylidene)-1*H*-inden-3-yl]acetic acid **D15** or a pharmaceutically acceptable salt thereof.

23. The compound of claim 16, wherein the compound is (*Z*)-2-(5-fluoro-2-methyl-1-(3-phenoxybenzylidene)-1*H*-inden-3-yl)acetic acid **D18** or a pharmaceutically acceptable salt thereof.

24. The compound of claim 16, wherein the compound is 2-[(1*Z*)-5,7-difluoro-1-(3-(phenoxy)benzylidene)-2-methyl-1*H*-inden-3-yl]-acetic acid **D20** or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition comprising the compound of any one of claims 1 to 24, or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and a pharmaceutically acceptable excipient.

26. Use of the compound of any one of claims 1 to 24 in the manufacture of a medicament for treating, preventing, or ameliorating one or more symptoms of a fibrotic disease; optionally wherein the fibrotic disease is a metabolic disease; or wherein the fibrotic disease is a liver disease; or wherein the fibrotic disease is nonalcoholic fatty liver disease (NAFLD); or

wherein the fibrotic disease is nonalcoholic steatohepatitis (NASH).

27. Use of the compound of any one of claims 1 to 24 in the manufacture of a medicament for treating, preventing, or ameliorating one or more symptoms of a proliferative disease; optionally wherein the proliferative disease is cancer.